KR20220000203A - A method for preparing tinea pedis-treating medicine and the tinea pedis-treating medicine prpared therefrom - Google Patents
A method for preparing tinea pedis-treating medicine and the tinea pedis-treating medicine prpared therefrom Download PDFInfo
- Publication number
- KR20220000203A KR20220000203A KR1020200077867A KR20200077867A KR20220000203A KR 20220000203 A KR20220000203 A KR 20220000203A KR 1020200077867 A KR1020200077867 A KR 1020200077867A KR 20200077867 A KR20200077867 A KR 20200077867A KR 20220000203 A KR20220000203 A KR 20220000203A
- Authority
- KR
- South Korea
- Prior art keywords
- foot
- athlete
- medicine
- treatment
- medical grade
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Alternative & Traditional Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
본 발명은 의약(medicine)의 제조 방법에 관한 것으로, 특히 무좀 치료약(tinea pedis-treating medicine)의 제조 방법에 관한 것이고, 또한 그 방법에 의해 제조된 무좀 치료약에 관한 것이다.The present invention relates to a method for manufacturing a medicine, and more particularly, to a method for manufacturing tinea pedis- treating medicine, and also to an athlete's foot treatment prepared by the method.
무좀(tinea pedis)은 일반적인 피부 질병으로, 일반적으로 발 부분의 피부에 붉은 반점, 가려움증 및 피부 박리를 유발한다. 무좀은 심각한 질병은 아니지만, 밤 낮으로 사람을 괴롭힐 것이고, 정상적인 업무와 생활에 영향을 미칠 것이고; 중증 무좀 환자는 피부 궤양 및 고름 배출을 앓을 것이며, 심지어 걸을 수 없다. 현재, 무좀의 치료를 위한 많은 의약이 존재하지만, 느린 효과를 갖거나 불량한 효과 또는 높은 재발율을 갖기 때문에, 환자의 필요를 충족시킬 수 없다.Athlete's foot ( tinea pedis) is a common skin disease that causes red spots, itching, and peeling of the skin, usually on the skin of the feet. Although athlete's foot is not a serious disease, it will plague people day and night, and will affect normal work and life; Patients with severe athlete's foot will suffer from skin ulcers and discharge of pus, and may not even be able to walk. At present, many drugs exist for the treatment of athlete's foot, but they cannot meet the needs of patients because they have a slow effect or have a poor effect or a high recurrence rate.
본 발명의 목적은 무좀 치료약의 제조 방법 및 그 방법에 의해 제조된 무좀 치료약을 제공하는 것이다. 본 발명의 제조 방법에 의해 제조된 무좀 치료약은 빠른 효과, 양호한 효과 및 낮은 재발율을 가지며, 기존의 무좀 치료약의 단점을 극복한다.It is an object of the present invention to provide a method for preparing a drug for treating athlete's foot and a drug for treating athlete's foot prepared by the method. The treatment for athlete's foot manufactured by the method of the present invention has a rapid effect, good effect and low recurrence rate, and overcomes the disadvantages of the existing treatment for athlete's foot.
본 발명에 따르면, 무좀 치료약의 제조 방법은 하기 단계를 포함한다:According to the present invention, a method for preparing a drug for treating athlete's foot comprises the following steps:
1) 하기 원료:1) The following raw materials:
시나몬(cinnamon) 분말 60 내지 80 mg, 0.2-0.3 wt.% 벤조산 100 내지 120 mg, 미코나졸 니트레이트(miconazole nitrate) 8 내지 10 mg, 5 내지 10 wt.% 살리실산 60 내지 80 mg, 클로베타솔 프로피오네이트(clobetasol propionate) 1 내지 3 mg, 의료용 바셀린(vaseline) 5 내지 7 mg, 및 75 wt.% 의료용 에탄올 1ml를 준비(preparing)하는 단계.Cinnamon powder 60-80 mg, 0.2-0.3 wt.% benzoic acid 100-120 mg, miconazole nitrate 8-10 mg, 5-10 wt.% salicylic acid 60-80 mg, clobetasol Preparing 1-3 mg of clobetasol propionate, 5-7 mg of medical grade vaseline, and 1 ml of 75 wt.% medical grade ethanol.
바람직하게는, 원료 및 그의 함량은 하기와 같다:Preferably, the raw material and its content are as follows:
시나몬 분말 70 내지 80 mg, 0.2 내지 0.3 wt.% 벤조산 100 내지 115 mg, 미코나졸 니트레이트 8 내지 9 mg, 5 내지 10 wt.% 살리실산 60 내지 75 mg, 클로베타솔 프로피오네이트 2 내지 3 mg, 의료용 바셀린 6 내지 7 mg, 및 75 wt.% 의료용 에탄올 1ml;Cinnamon powder 70-80 mg, 0.2-0.3 wt.% benzoic acid 100-115 mg, miconazole nitrate 8-9 mg, 5-10 wt.% salicylic acid 60-75 mg, clobetasol propionate 2-3 mg , 6-7 mg of medical grade petrolatum, and 1 ml of 75 wt.% medical grade ethanol;
2) 필요한 시나몬 분말, 0.2-0.3 wt.% 벤조산, 5-10 wt.% 살리실산, 미코나졸 니트레이트, 클로베타솔 프로피오네이트, 및 의료용 바셀린을 필요한 75 wt.% 의료용 에탄올에 순차적으로 첨가하고, 생성물을 균일하게 교반하여 무좀 치료약을 수득하는 단계; 및 2) sequentially add the required cinnamon powder, 0.2-0.3 wt.% benzoic acid, 5-10 wt.% salicylic acid, miconazole nitrate, clobetasol propionate, and medical grade petrolatum to the required 75 wt.% medical grade ethanol; , to obtain a treatment for athlete's foot by uniformly stirring the product; and
3) 상기 수득된 무좀 치료약을 각각 25 내지 50 mL로 병에 분할 충전(split charging)하고, 밀봉하는 단계. 3) Split charging the obtained athlete's foot treatment drug into 25 to 50 mL bottles, respectively, and sealing.
본 발명의 무좀 치료약의 사용 방법(외용)은The method of use (external use) of the athlete's foot treatment of the present invention is
무좀 치료약을 환부에 하루 2회 도포하는 것; 및 증상이 사라진 후 또 다른 1-2주 동안 무좀 치료약을 계속 도포하는 것을 포함하며, 무좀 치료약을 도포하는 동안에는 알코올 및 매운 음식의 섭취가 금지된다. 이 치료약은 알코올 및 이 치료약에 알레르기가 있는 사람에게는 금지된다는 것을 주목해야 하며; 이 치료약은 알레르기가 있는 사람과 수유 중인 여성의 경우 주의해서 사용해야 한다는것을 주목해야 한다.Applying athlete's foot treatment to the affected area twice a day; and continuing to apply the athlete's foot treatment for another 1-2 weeks after the symptoms disappear, while alcohol and spicy food are prohibited while the athlete's foot treatment is applied. It should be noted that this medicine is contraindicated in people allergic to alcohol and this medicine; It should be noted that this treatment should be used with caution in people with allergies and in lactating women.
본 발명의 무좀 치료약은 상승 효과를 충분히 발휘하기 위해 한약 원료 및 서양 의약 원료를 조합하여 사용하며; 한약 원료와 서양 의약 원료의 합리적인 비율은 빠른 효과, 양호한 효과 및 낮은 재발율의 특징을 부여한다. 본 발명의 무좀 치료약을 도포한 후, 환자는 통증 없이 약간의 자극을 느낄 것이고; 무좀 치료약은 도포 후 빠르게 증발하는 에탄올을 함유하고, 도포 후 피부가 마르지 않도록 소량의 바셀린을 함유하며; 무좀 치료약은 사용하기 쉽고 도포 후 환자가 편안함을 느끼도록 만들 것이다. 본 발명의 무좀 치료약은 최대 98%의 총 효능률, 최대 93%의 치유율(curing effect), 및 2%의 비효능률(ineffectiveness rate)로, 3000명 이상의 환자를 치료하기 위해 사용되었다. 일반적으로, 무좀 치료약을 도포한 후, 30분 후에 가려움증 증상이 완화되기 시작하고; 1-3일 후에 (중등도 환자의 경우) 관련 증상이 사라지거나 (중증도 환자의 경우) 유의하게 완화될 것이고; 증상이 사라진 후, 치료약을 다른 1-2주 동안 계속 도포하면, 치유 효과(curing effect)가 달성될 것이며; 재발율은 낮다.The treatment for athlete's foot of the present invention uses a combination of herbal and western medicinal raw materials to sufficiently exhibit a synergistic effect; A reasonable ratio of herbal raw materials and Western medicine raw materials gives the characteristics of fast effect, good effect and low recurrence rate. After application of the athlete's foot treatment of the present invention, the patient will feel slight irritation without pain; The athlete's foot treatment contains ethanol that evaporates quickly after application, and contains a small amount of petrolatum so that the skin does not dry out after application; The athlete's foot treatment is easy to use and will make the patient feel comfortable after application. The athlete's foot therapeutic agent of the present invention has a total efficacy of up to 98%, a curing effect of up to 93%, and an ineffectiveness rate of 2%, and has been used to treat more than 3000 patients. In general, after 30 minutes of application of the athlete's foot treatment, the itching symptoms begin to subside; After 1-3 days (for moderate patients) the relevant symptoms will disappear or (for moderate patients) will significantly relieve; After the symptoms disappear, a curing effect will be achieved if the treatment is continued for another 1-2 weeks; The recurrence rate is low.
본 발명의 무좀 치료약은 제조가 간단하고, 비용이 저렴하고, 효과가 양호하며, 적은 지출을 필요로하면서도 대부분의 환자의 필요를 충족시킬 수 있고, 단시간 내에 통증을 완화시킬 수 있고, 낮은 재발율을 가져서, 환자가 정상적인 업무 및 생활에 돌아올 수 있도록 돕는다.The agent for treating athlete's foot of the present invention is simple to manufacture, inexpensive, and has good effects, can satisfy the needs of most patients while requiring little expenditure, can relieve pain within a short time, and has a low recurrence rate. to help the patient return to normal work and life.
본 발명에 의해 필요한 원료 및 장치는 상업적으로 입수가능하다.The raw materials and equipment required by the present invention are commercially available.
실시예 1Example 1
무좀 치료약은 상기 무좀 치료약의 제조 방법에 따라 제조되며, 여기서 단계 1)에서, 원료 및 그의 함량은 하기와 같고: 시나몬 분말 60000 mg, 벤조산 100000 mg, 살리실산 80000 mg, 미코나졸 니트레이트 10000 mg, 클로베타솔 프로피오네이트 1000 mg, 의료용 바셀린 5000 mg, 및 의료용 에탄올 1000ml; 단계 3)에서, 무좀 치료약은 각 병에 25mL 씩 분할 충전된다.The athlete's foot treatment drug is prepared according to the method for preparing the athlete's foot treatment drug, wherein in step 1), the raw material and its content are as follows: cinnamon powder 60000 mg, benzoic acid 100000 mg, salicylic acid 80000 mg, miconazole nitrate 10000 mg, chloro 1000 mg of betasol propionate, 5000 mg of petrolatum for medical use, and 1000 ml of medical ethanol; In step 3), the athlete's foot treatment drug is dividedly filled in 25mL each bottle.
실시예 2Example 2
무좀 치료약은 상기 무좀 치료약의 제조 방법에 따라 제조되며, 여기서 단계 1)에서, 원료 및 그의 함량은 하기와 같고: 시나몬 분말 80000 mg, 벤조산 120000 mg, 살리실산 60000 mg, 미코나졸 니트레이트 8000 mg, 클로베타솔 프로피오네이트 3000 mg, 의료용 바셀린 7000 mg, 및 의료용 에탄올 1000ml; 단계 3)에서, 무좀 치료약은 각 병에 50mL 씩 분할 충전된다.Athlete's foot treatment drug is prepared according to the method for preparing the athlete's foot treatment drug, wherein in step 1), the raw material and its content are as follows: cinnamon powder 80000 mg, benzoic acid 120000 mg, salicylic acid 60000 mg, miconazole nitrate 8000 mg, chloro Betasol propionate 3000 mg, medical grade petrolatum 7000 mg, and medical grade ethanol 1000 ml; In step 3), the athlete's foot treatment drug is filled in 50mL portions in each bottle.
실시예 3Example 3
무좀 치료약은 상기 무좀 치료약의 제조 방법에 따라 제조되며, 여기서 단계 1)에서, 원료 및 그의 함량은 하기와 같고: 시나몬 분말 70000 mg, 벤조산 115000 mg, 살리실산 75000 mg, 미코나졸 니트레이트 9000 mg, 클로베타솔 프로피오네이트 2000 mg, 의료용 바셀린 6000 mg, 및 의료용 에탄올 1000ml; 단계 3)에서, 무좀 치료약은 각 병에 25mL 씩 분할 충전된다.The athlete's foot treatment drug is prepared according to the method for preparing the athlete's foot treatment drug, wherein in step 1), the raw material and its content are as follows: cinnamon powder 70000 mg, benzoic acid 115000 mg, salicylic acid 75000 mg, miconazole nitrate 9000 mg, chloro Betasol propionate 2000 mg, medical grade petrolatum 6000 mg, and medical grade ethanol 1000 ml; In step 3), the athlete's foot treatment drug is dividedly filled in 25mL each bottle.
임상 관찰의 요약Summary of Clinical Observations
I. 무좀의 진단 기준: 발 부분이 붉은 반점, 가려움증, 및 피부 박리를 앓고 있고, 심지어 피부 궤양 및 고름 배출을 심각하게 앓고 있다.I. Diagnosis criteria for athlete's foot: The feet suffer from red spots, itching, and peeling of the skin, and even seriously suffer from skin ulcers and discharge of pus.
II. 본 발명의 무좀 치료약의 사용 방법(외용)은: 무좀 치료약을 환부에 하루 2회 도포하는 것; 및 증상이 사라진 후 또 다른 1-2주 동안 무좀 치료약을 계속 도포하는 것을 포함하며, 무좀 치료약을 도포하는 동안에는 알코올 및 매운 음식의 섭취가 금지된다. 이 치료약은 알코올 및 이 치료약에 알레르기가 있는 사람에게는 금지된다는 것을 주목해야 하며; 이 치료약은 알레르기가 있는 사람과 수유 중인 여성의 경우 주의해서 사용해야 한다는것을 주목해야 한다.II. The method of using the athlete's foot treatment of the present invention (external use) includes: applying the athlete's foot treatment to the affected area twice a day; and continuing to apply the athlete's foot treatment for another 1-2 weeks after the symptoms disappear, while alcohol and spicy food are prohibited while the athlete's foot treatment is applied. It should be noted that this medicine is contraindicated in people allergic to alcohol and this medicine; It should be noted that this treatment should be used with caution in people with allergies and in lactating women.
III. 치료 효과의 평가 기준:III. Criteria for evaluation of therapeutic effect:
1. 효능: 증상이 완전히 사라지고, 피부가 정상으로 회복되며, 8 내지 12개월 후에 재발한다. 1. Efficacy: The symptoms disappear completely, the skin returns to normal, and it recurs after 8 to 12 months.
2. 치유: 증상이 완전히 사라지고, 피부가 정상으로 회복되며, 재발하지 않는다. 2. Healing: The symptoms disappear completely, the skin returns to normal, and there is no recurrence.
3: 비효능: 가려움증이 완화되며, 증상이 약간 변한다. 3: Ineffectiveness: Itching is relieved, and symptoms are slightly changed.
IV. 치료 효과: 총 300명의 환자가 임상적으로 관찰되었으며, 여기서 60 명의 환자는 6개월 이하 동안 무좀을 앓았고, 140 명의 환자는 1 내지 5년 동안 무좀을 앓았고, 100 명의 환자는 10년 이상 동안 무좀을 앓았다. 결과적으로, 294 명의 환자는 효과적으로 치료되었고; 279 명의 환자가 치유되었고, 15 명의 환자가 치유 후 재발하였으며, 6명의 환자가 비효과적으로 치료되어서, 98%의 총 효능률, 93%의 치유율, 5%의 재발율, 및 2%의 비효능률을 달성하였다.IV. Therapeutic effect: A total of 300 patients were clinically observed, where 60 patients had athlete's foot for up to 6 months, 140 patients had athlete's foot for 1 to 5 years, and 100 patients had athlete's foot for more than 10 years. had athlete's foot As a result, 294 patients were effectively treated; 279 patients healed, 15 patients relapsed after healing, and 6 patients were treated ineffectively, resulting in a total efficacy rate of 98%, a cure rate of 93%, a recurrence rate of 5%, and an inefficiency rate of 2%. achieved.
전형적인 케이스typical case
1. 쭈(Zhou)(23세 여성)는 10년 이상 무좀을 앓았고, 그 동안 때때로 호전되었다가 때때로 참을 수 없을 정도의 고통스러움을 느꼈고, 10 종류 이상의 무좀 치료약을 사용했지만, 효과는 좋지 않았다. 그녀의 두 발은 통증과 가려움증을 동반한 농포성 습식 무좀을 앓았다. 본 발명의 무좀 치료약으로 치료한 후, 가려움증이 당일에 사라졌고; 3일 후 관련 증상이 유의하게 완화되었고; 1주 후 증상이 사라졌으며; 그 후 또 다른 1주 동안 치료약을 계속 도포하였고, 무좀은 지금까지 재발하지 않았다. 1. Zhou (23 years old female) suffered from athlete's foot for more than 10 years. During that time, she sometimes improved and sometimes felt unbearable pain. She used more than 10 types of athlete's foot treatment, but the effect was not good. . Both of her feet suffered from pustular wet athlete's foot, which was painful and itchy. After treatment with the agent for treating athlete's foot of the present invention, the itch disappeared on the same day; After 3 days, the associated symptoms were significantly relieved; Symptoms disappeared after 1 week; After that, the treatment was continued for another week, and athlete's foot has not recurred so far.
2. 리(Li)(28세 남성)는 4년 동안 무좀을 앓았고, 그의 두 발은 참을 수 없는 가려움증과 통증을 동반한 표재성궤양형성물질성(anabrotic) 습식 무좀을 앓았다. 본 발명의 무좀 치료약으로 치료한 후, 1일 후 가려움증과 통증이 사라졌고; 3일 후 관련 증상이 완화되었고; 1주 후 증상이 사라졌으며; 그 후 또 다른 1주 동안 치료약을 계속 도포하였고, 무좀은 지금까지 재발하지 않았다.2. Li (28 years old male) suffered from athlete's foot for 4 years and had superficial anabrotic wet athlete's foot with unbearable itching and pain in both feet. After treatment with the treatment agent for athlete's foot of the present invention, itching and pain disappeared after 1 day; After 3 days the associated symptoms were relieved; Symptoms disappeared after 1 week; After that, the treatment was continued for another week, and athlete's foot has not recurred so far.
3. 짱(Zhang)(30세 남성)은 무좀을 앓았고 약국에서 도포하기 위한 7 또는 8 종류의 무좀 치료약을 구입했지만, 효과가 좋지 않아서 무좀이 반복적으로 재발하였고, 그의 두 발은 농포를 형성하였고, 고름 배출, 피부 박리, 가려움증 및 통증을 동반하였다. 본 발명의 무좀 치료약으로 치료한 후, 2일 째에 가려움증이 사라졌고; 3일 후에 관련 증상이 유의하게 완화되었고; 1주 후에 증상이 사라졌으며; 그 후 또 다른 1주 동안 치료약을 계속 도포하였고, 무좀은 지금까지 재발하지 않았다.3. Zhang (30 years old male) suffered from athlete's foot and bought 7 or 8 types of athlete's foot treatment for application at the pharmacy, but the effect was not good and the athlete's foot recurred repeatedly, and his feet formed pustules. It was accompanied by pus discharge, skin peeling, itching and pain. After treatment with the agent for treating athlete's foot of the present invention, itching disappeared on the second day; After 3 days, the associated symptoms were significantly relieved; Symptoms disappeared after 1 week; After that, the treatment was continued for another week, and athlete's foot has not recurred so far.
4. 송(Song)(48세 여성) 은 10년 이상 무좀을 앓았고 많은 의약을 사용했지만 치유되지 않았다. 경제적인 어려움 때문에, 그녀는 증상이 심할 때만 의약을 도포하였고, 증상이 가벼울 때는 의약을 도포하지 않았다. 발 바닥의 오래된 피부는 매우 두꺼웠고, 노출된 새 살은 붉은 반점을 앓았고 물집, 통증, 및 가려움증을 동반하였다. 본 발명의 무좀 치료약으로 치료한 후, 오래된 피부는 점진적으로 박리가 되었고, 가려움증은 사라졌고 1주 후 새 피부가 자랐고; 발 바닥 전체의 오래된 피부는 완전히 박리되었고 또 다른 1주 후 무좀이 치유되었으며; 그 후 또 다른 10일 동안 치료약을 계속 도포하였고, 무좀은 지금까지 4년 이상 동안 재발하지 않았다.4. Song (a 48-year-old female) suffered from athlete's foot for more than 10 years and used many medications, but it did not heal. Due to financial difficulties, she applied the medication only when the symptoms were severe, and did not apply the medication when the symptoms were mild. The old skin on the sole of the foot was very thick, and the exposed new flesh had red spots and was accompanied by blisters, pain, and itching. After treatment with the treatment agent for athlete's foot of the present invention, the old skin gradually peeled off, the itching disappeared, and new skin grew after 1 week; The old skin all over the sole of the foot was completely peeled off and athlete's foot healed after another week; After that, the treatment was continued for another 10 days, and athlete's foot has not recurred for more than 4 years so far.
5. 짜오(Zhao)(26세 여성)는 무좀을 앓았고 상태가 심각하여 치료를 위해 외용약및 주입을 사용했지만, 효과는 좋지 않았다. 그녀의 두 발은 부었고 표재성궤양형성물질성이었고, 농포, 고름 배출, 및 참을 수 없는 통증 및 가려움증을 동반하였다. 항생제 경구 투여와 함께 본 발명의 무좀 치료약으로 치료한 후, 발은 붓지 않았고, 농포가 사라졌고 새로운 피부가 5일 후 자랐으며; 그후 항생제는 중단하였고 본 발명의 무좀 치료약은 또 다른 2주 동안 계속 도포하였고, 무좀이 치유되었으며 지금까지 2년 이상 동안 재발하지 않았다.5. Zhao (26 years old female) suffered from athlete's foot and her condition was so serious that she used topical drugs and injections for treatment, but the effect was not good. Her feet were swollen and superficial ulcerative, accompanied by pustules, pus discharge, and intolerable pain and itching. After treatment with the antibiotics for the treatment of athlete's foot of the present invention along with oral administration of antibiotics, the feet did not swell, the pustules disappeared, and new skin grew after 5 days; After that, the antibiotic was stopped and the athlete's foot treatment of the present invention was continued to be applied for another 2 weeks, and athlete's foot was cured and there was no recurrence for more than 2 years so far.
Claims (4)
1) 하기 원료:
시나몬(cinnamon) 분말 60 내지 80mg, 0.2-0.3 wt.% 벤조산 100 내지 120 mg, 미코나졸 니트레이트(miconazole nitrate) 8 내지 10 mg, 5 내지 10 wt.% 살리실산 60 내지 80 mg, 클로베타솔 프로피오네이트(clobetasol propionate) 1 내지 3 mg, 의료용 바셀린(vaseline) 5 내지 7 mg, 및 75 wt.% 의료용 에탄올 1ml를 준비(preparing)하는 단계;
2) 필요한 시나몬 분말, 벤조산, 살리실산, 미코나졸 니트레이트, 클로베타솔 프로피오네이트, 및 의료용 바셀린을 필요한 의료용 에탄올에 순차적으로 첨가하고, 생성물을 균일하게 교반하여 무좀 치료약을 수득하는 단계; 및
3) 상기 수득된 무좀 치료약을 각 병에 25 내지 50 mL로 분할 충전(split charging)하고, 밀봉하는 단계. A method for preparing a medicament for athlete's foot ( tinea pedis ), comprising the steps of:
1) The following raw materials:
Cinnamon powder 60-80 mg, 0.2-0.3 wt.% benzoic acid 100-120 mg, miconazole nitrate 8-10 mg, 5-10 wt.% salicylic acid 60-80 mg, clobetasol pro Preparing 1 to 3 mg of clobetasol propionate, 5 to 7 mg of medical grade vaseline, and 1 ml of 75 wt.% medical grade ethanol;
2) sequentially adding the necessary cinnamon powder, benzoic acid, salicylic acid, miconazole nitrate, clobetasol propionate, and medical petrolatum to the necessary medical grade ethanol, and uniformly stirring the product to obtain a drug for treating athlete's foot; and
3) Split charging the obtained athlete's foot treatment drug into 25 to 50 mL in each bottle, and sealing.
시나몬 분말 70 내지 80 mg, 0.2 내지 0.3 wt.% 벤조산 100 내지 115 mg, 미코나졸 니트레이트 8 내지 9 mg, 5 내지 10 wt.% 살리실산 60 내지 75 mg, 클로베타솔 프로피오네이트 2 내지 3 mg, 의료용 바셀린 6 내지 7 mg, 및 75 wt.% 의료용 에탄올 1ml.The method according to claim 1, wherein the raw material and its content are as follows:
Cinnamon powder 70-80 mg, 0.2-0.3 wt.% benzoic acid 100-115 mg, miconazole nitrate 8-9 mg, 5-10 wt.% salicylic acid 60-75 mg, clobetasol propionate 2-3 mg , 6-7 mg of medical grade petrolatum, and 1 ml of 75 wt.% medical grade ethanol.
시나몬 분말 70000 mg, 0.2 내지 0.3 wt.% 벤조산 115000 mg, 미코나졸 니트레이트 9000 mg, 5 내지 10 wt.% 살리실산 75000 mg, 클로베타솔 프로피오네이트 2000 mg, 의료용 바셀린 6000 mg, 및 75 wt.% 의료용 에탄올 1000ml.The method according to claim 2, wherein the raw material and its content are as follows:
Cinnamon powder 70000 mg, 0.2-0.3 wt.% benzoic acid 115000 mg, miconazole nitrate 9000 mg, 5-10 wt.% salicylic acid 75000 mg, clobetasol propionate 2000 mg, medical petrolatum 6000 mg, and 75 wt. % Medical grade ethanol 1000ml.
시나몬 분말 60 내지 80 mg, 0.2 내지 0.3 wt.% 벤조산 100 내지 120 mg, 미코나졸 니트레이트 8 내지 10 mg, 5 내지 10 wt.% 살리실산 60 내지 80 mg, 클로베타솔 프로피오네이트 1 내지 3 mg, 의료용 바셀린 5 내지 7 mg, 및 75 wt.% 의료용 에탄올 1ml.
An athlete's foot treatment prepared by the method for preparing the athlete's foot treatment according to any one of claims 1 to 3, comprising the following raw materials:
Cinnamon powder 60-80 mg, 0.2-0.3 wt.% benzoic acid 100-120 mg, miconazole nitrate 8-10 mg, 5-10 wt.% salicylic acid 60-80 mg, clobetasol propionate 1-3 mg , 5 to 7 mg of medical grade petrolatum, and 1 ml of 75 wt.% medical grade ethanol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200077867A KR20220000203A (en) | 2020-06-25 | 2020-06-25 | A method for preparing tinea pedis-treating medicine and the tinea pedis-treating medicine prpared therefrom |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200077867A KR20220000203A (en) | 2020-06-25 | 2020-06-25 | A method for preparing tinea pedis-treating medicine and the tinea pedis-treating medicine prpared therefrom |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20220000203A true KR20220000203A (en) | 2022-01-03 |
Family
ID=80081352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020200077867A KR20220000203A (en) | 2020-06-25 | 2020-06-25 | A method for preparing tinea pedis-treating medicine and the tinea pedis-treating medicine prpared therefrom |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20220000203A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101120033B1 (en) * | 2011-04-23 | 2012-03-06 | 임일형 | A liquid waterproof stuff |
-
2020
- 2020-06-25 KR KR1020200077867A patent/KR20220000203A/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101120033B1 (en) * | 2011-04-23 | 2012-03-06 | 임일형 | A liquid waterproof stuff |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108853312B (en) | Polycinnamic alcohol external gel and preparation method thereof | |
| US5583120A (en) | Hyaluronic acid-urea pharmaceutical compositions and uses | |
| CN101417060B (en) | Plaster capable of treating trauma, traumatic injury, alopecia areata and burn and scald | |
| US6780439B2 (en) | Wound treatment solution and method for using same | |
| KR20110074513A (en) | Topical treatment of skin infection | |
| KR20220000203A (en) | A method for preparing tinea pedis-treating medicine and the tinea pedis-treating medicine prpared therefrom | |
| US10960011B2 (en) | Compositions for the treatment of ischemic ulcers and stretch marks | |
| KR20210156391A (en) | A method for preparing beriberi-treating medicine and the beriberi-treating medicine prepared therefrom | |
| US3039927A (en) | Pharmaceutical composition comprising aspirin and sorbitol | |
| KR20220029113A (en) | A method for preparing beriberi-treating medicine and the beriberi-treating medicine prepared therefrom | |
| KR20220023421A (en) | A method for preparing beriberi-treating medicine and the beriberi-treating medicine prepared therefrom | |
| Günther | Topical administration of vitamin A acid (retinoic acid) in palmar keratoses: callosities, hyperkeratotic eczema, hypertrophic lichen planus, pityriasis rubra pilaris | |
| Motley | Pseudoporphyria due to dyazide in a patient with vitiligo. | |
| CN1186068C (en) | Externally applied Chinese medicine with functions of diminishing inflammation, promoting granulation, stopping itch and stopping pain and its prepn process | |
| CN108635362A (en) | A kind of pharmaceutical composition for treating diabetes | |
| CN1086125C (en) | Externally used medicine for treating tinea | |
| Rodriguez et al. | Lobular panniculitis associated with ciprofloxacin. | |
| Majumdar et al. | Reversible hyperpigmentation associated with high dose hydroxyurea. | |
| JP3187806B2 (en) | External preparation for treating atopic dermatitis containing nitroimidazole compound | |
| RU2143262C1 (en) | Agent "vitaprokt" for treatment of patients with hemorrhoid | |
| Chaudhary et al. | A report of a non-healing burn wound managed through Ayurveda | |
| DE102020121939A1 (en) | METHOD OF PREPARING BERIBERI TREATMENT MEDICINE AND THE PREPARED BERIBERI TREATMENT MEDICINE | |
| CN108066570B (en) | Traditional Chinese medicine extract for diminishing inflammation and relieving pain after haemorrhoid surgery and application thereof | |
| CN113521094A (en) | Emulsion ointment for treating eczema and preparation method thereof | |
| Revici et al. | Anti-hemorrhagic action of n-butanol in advanced cancer |